Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a high risk of embolic stroke (cause in 15% of all strokes and 30% of strokes in those >75 years of age). Anticoagulation with warfarin will reduce stroke risk by about two thirds. The main risks of anticoagulation, namely bleeding, can be minimized by maintaining anticoagulation control within the international normalized range range of 2.0 to 3.0 (target: 2.5). To have a public health impact, patients with AF need efficient and correct identification, with appropriate treatment directed at those patients at most risk from the condition. Copyright © 2009 by Thieme Medical Publishers, Inc.

Original publication




Journal article


Seminars in Thrombosis and Hemostasis

Publication Date





543 - 547